Governance

The SGC is governed by a Board of Directors, composed by representatives of our funders and Scientific Committees which deliberate and provide directions to our research activities.

The SGC Organization is overseen by its CEO Prof. Aled Edwards and each of the SGC labs is directed by a Chief Scientist.

SGC Board


Board of Directors

Board Observers

SGC Management Team

Cindy Bell, Genome Canada Allison Barr CA Ministry of Research and Innovation Cheryl Arrowsmith CSO SGC Toronto
Adrian J. Carter Boehringer Ingelheim Robert A. Blouin Dean, SOP UNC Chas Bountra CSO SGC Oxford
Tom Collins (Secretary) Wellcome Trust Carlos de Brito Cruz FAPESP Paul Van Damme CFO SGC Toronto
Michael Dunn Wellcome Trust Paul Lasko  McGill University Amy Donner Communications
Ronan O’Hagan Merck US Kumar Saikatendu Takeda Aled Edwards CEO SGC Toronto
Stephen Hitchcock Takeda   Jon Elkins CSO SGC Unicamp
Trevor Howe Janssen Cilag UK   Stefan Knapp CSO SGC Frankfurt
Spiros Liras Pfizer   Michael Sundström CSO SGC Karolinska
Tetsuyuki Maruyama (Chairman) Dementia Discovery Fund   Timothy Willson CSO SGC UNC
Anke Mueller-Fahrnow Bayer Pharma    
Nils Ostermann Novartis    
Saul Rosenberg Abbvie    

 

Chemical Probes


Scientific Committee

Julian Blagg Institute of Cancer Research, UK
Stephen Burley Rutgers University
Stephen Frye UNC
Paul Thompson University of Massachusetts

 

Joint Management Committee

Marcus Bauser Bayer Ulrich Betz Merck Europe Guido Boehmelt BI
Ursula Egner Bayer Christian Fischer Merck US Mathias Frederiksen Novartis
Lindsey Ingerman James UNC Stefan Jaekel Merck Europe David Jenkinson (observer) Brain Tumour Charity
Jian Jin MSSM Laetitia Martin BI Hisanori Matsui, Takeda
Anke Mueller-Fahrnow Bayer Cora Mund Bayer Benjamin Nicholson Merck US
Ronan O'Hagan Merck US Nils Ostermann Novartis Dafydd Owen Pfizer  
Vineet Pande Janssen Simon Ridley (observer), Myeloma UK Friedrich Rippman Merck Europe
Kumar Saikatendu Takeda Chris Tse Abbvie Zhengtian Yu China-Novartis

Structure & TEP


Joint Management Committee

Maria Argiriadi Abbvie Lance Bigelow Abbvie Chas Bountra SGC
Rajiv Chopra Novartis Kirk Clark Novartis Carien Dekker Novartis
Ievgeniia Dubrovska Abbvie Ursula Egner Bayer Trevor Howe Janssen
Terry Hughes Janssen Veli-Pekka Jaakola Novartis Sandra Jacob Novartis
Stefan Jaekel Merck Europe Clarissa Jakob Abbvie Russell Judge Abbvie
Kenton Longenecker Abbvie Mahindra Makhija Takeda John Mathias Pfizer
Cora Mund Bayer Nils Ostermann Novartis Dafydd Owen Pfizer
Vineet Pande Janssen Jayvardhan Pandit Pfizer Wei Qiu Abbvie
Xiayang Qiu Pfizer Friedrich Rippman Merck Europe Heiko Runz Merck US
Kumar Saikatendu Takeda Alex Shoemaker Abbvie Fai Siu Novartis
Vincent Stoll Abbvie Chaohong Sun Abbvie Chris Tse Abbvie
Amélia Viana Boehringer Ingelheim    

 

TEP Evaluation Group 

Tom Collins Wellcome Trust Mike Dunn Wellcome Trust Jane Endicott Newcastle
Mike Ferguson Dundee Tim Harrison Queen’s Belfast Louise Jones MRC
Raj Parekh Advent Life Sciences Peter Ratcliffe Oxford & Crick Institute Kumar Saikatendu Takeda
Richard Seabrook Wellcome Simon Word Sussex  

 

Tissue Platforms


Oncology Joint Management Committee 

Ellen Berg DiscoveRx Mark Bittinger Merck US Sophia Blake Boehringer Ingelheim
Erwin Boghaert AbbVie Bernard Haendler Bayer Sabine Hoff Bayer
John Newcomb Takeda Thomas Paul Pfizer Elizabeth Rex Janssen
Kumar Saikatendu Takeda Patricia Soulard Merck Europe Amélia Viana Boehringer Ingelheim

 

Inflammation Joint Management Committee

Ellen Berg DiscoveRx Ina Goreticke Bayer Bernard Haendler Bayer
Perry Hall Pfizer Sabine Hoff Bayer Andreas Katopodis Novartis
Matt Mackey Merck US Jesus Paez-Cortez  Abbive Meera Ramanujam Boehringer Ingelheim
Elizabeth Rex Janssen Kumar Saikatendu Takeda Patricia Soulard Merck Europe
Amélia Viana Boehringer Ingelheim    

 

Neurobiology Joint Management Committee

Ellen Berg DiscoveRx Sophia Blake BI Thomas Durcan McGill
Ted Fon McGill Matthew Kennedy Merck US Hisanori Matsui Takeda
Elizabeth Rex Janssen Matt Townsend Abbvie Amélia Viana Boehringer Ingelheim

 

Target Prioritization Networks


Cancer (TPN)

Matt Baker ThermoFisher Alison Banham Oxford Georg Beckmann Bayer
Christopher Claiborne Takeda Guowei Fang AbbVie Margaret Frame Edinburgh
Freddie Hamdy Oxford Timothy Harrison Queens University Belfast Manfred Koegl BI
Ralph Lindemann Merck Europe Hisanori Matsui Takeda Ultan McDermott Sanger
Willem Ouwehand Cambridge Thomas A Paul Pfizer Saul Rosenberg AbbVie
Heiko Runz Merck Kumar Saikatendu Takeda Patricia Soulard Merck Europe
Chris Tse Abbvie Ashok Venkitaraman MRC Cambridge Amélia Viana Boehringer Ingelheim
Ian Waddell CRUK Manchester Paul Workman ICR Paul Wyatt Dundee

 

Metabolic disease (TPN)

Matt Baker ThermoFisher Georg Beckmann  Bayer Guido Boehmelt Boehringer Ingelheim
Christine Bulawa Pfizer Peter Clayton Institute of Child Health, London Ben Davis Dept of Chemistry, Oxford
Anna Gloyn OCDEM, Oxford William Newman Manchester Centre for Genomic Medicine Steve O'Rahilly University of Cambridge
Frances Platt Dept of Pharmacology, Oxford Florian Prinz Bayer Steve Pullen BI
Heiko Runz  Genetics, Merck Kumar Saikatendu Takeda Rajesh Thakker OCDEM, Oxford
Yoshiyuki Tsujihata Takeda Amélia Viana Boehringer Ingelheim  

 

Neurobiology (TPN)

Praveen Anand Imperial Matt Baker ThermoFisher Guido Boehmelt BI
Zameel Cader Oxford David Collier Lilly John Davis ODDI, Oxford
Kay Davies Oxford Elena di Daniel Oxford Ted Fon McGill
John Geddes Oxford Bastian Hengerer BI, Biberach Matthew Hurles Sanger, Cambridge
Nick Irving Oxford John Isaac JJ Innovation Hisanori Matsui Takeda
Stefan McDonough Pfizer Patricio O'Donnell Pfizer Mike Owen Cardiff
Rabinder Prinjha GSK David Reynolds ARUK Heiko Runz Merck, Genetics
Kumar Saikatendu Takeda Jenny Taylor Oxford Amélia Viana Boehringer Ingelheim
glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03